Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia.

Frontiers in nephrology Pub Date : 2024-10-22 eCollection Date: 2024-01-01 DOI:10.3389/fneph.2024.1459425
Amit Joharapurkar, Vrajesh Pandya, Harilal Patel, Mukul Jain, Ranjit Desai
{"title":"Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia.","authors":"Amit Joharapurkar, Vrajesh Pandya, Harilal Patel, Mukul Jain, Ranjit Desai","doi":"10.3389/fneph.2024.1459425","DOIUrl":null,"url":null,"abstract":"<p><p>Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review summarizes the preclinical and clinical profile of desidustat which led to its approval and clinical use in India.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1459425"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534831/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fneph.2024.1459425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review summarizes the preclinical and clinical profile of desidustat which led to its approval and clinical use in India.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Desidustat:治疗慢性肾功能衰竭所致贫血的新型 PHD 抑制剂。
Desidustat 是一种低氧诱导因子-脯氨酰羟化酶 (HIF-PH) 小分子抑制剂,由 Zydus Lifesciences 发现并开发,用于治疗与慢性肾病 (CKD) 相关的贫血。本综述概述了地司他的临床前和临床概况,地司他在印度获得批准并投入临床使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Vascular injury in glomerulopathies: the role of the endothelium. Editorial: Insights in glomerular disease. The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage. Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review. Analyzing body composition in living kidney donors: impact on post-transplant kidney function.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1